Join
Live feed
·
PRReleasevia Quantisnow
Iovance Biotherapeutics Inc. logo

Iovance Biotherapeutics Raises Full Year 2026 Revenue Guidance to $410 to $420 Million

ByQuantisnow·Wall Street's wire, on your screen.
IOVA· Iovance Biotherapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track IOVA (Iovance Biotherapeutics Inc.) and more on Quantisnow.